Changchun GeneScience Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1948-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://english.ciac.cas.cn/
Clinical Trials
84
Active:5
Completed:27
Trial Phases
5 Phases
Phase 1:29
Phase 2:15
Phase 3:18
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (79 trials with phase data)• Click on a phase to view related trials
Phase 1
29 (36.7%)Phase 3
18 (22.8%)Phase 2
15 (19.0%)Not Applicable
9 (11.4%)Phase 4
8 (10.1%)A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
Not Applicable
Recruiting
- Conditions
- Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaMulticenter Observational Study
- Interventions
- Drug: Nanocrystalline Megestrol Acetate
- First Posted Date
- 2025-11-21
- Last Posted Date
- 2025-11-21
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 495
- Registration Number
- NCT07243379
- Locations
- 🇨🇳
Henan Cancer Hospital, Affiliated to Zhengzhou University, Zhengzhou, Henan, China
GenSci139 in Patients With Advanced Solid Tumors
- First Posted Date
- 2025-11-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT07230977
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Cancer Hospital, Jinan, Shandong, China
Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Nano-crystalline Megestrol Acetate Oral SuspensionOther: Standard Therapy
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 134
- Registration Number
- NCT07150663
- Locations
- 🇨🇳
Tongji Hospital, TongjiMedical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
Not Applicable
Not yet recruiting
- Conditions
- EfficacySafetyMegestrol AcetateAdult Subject
- Interventions
- Drug: Low dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: Medium dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: High dose of Megestrol Acetate Oral Suspension combined with standard therapyDrug: Megestrol Acetate Oral Suspension Placebo combined with standard therapy
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT07130617
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets
Not Applicable
Recruiting
- Conditions
- Hyperprolactinemia
- Interventions
- Drug: Cabergoline tabletsDrug: Bromocriptine mesylate tablets
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Target Recruit Count
- 382
- Registration Number
- NCT07124221
- Locations
- 🇨🇳
Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next
News
No news found